Biomarin Up After Q3 Earnings: Here's Everything You Need to Know

Core Insights - BioMarin Pharmaceutical missed both revenue and earnings estimates in the third quarter, indicating potential challenges in financial performance [1] Financial Performance - The company reported lower than expected revenue and earnings for the third quarter [1] - Despite the earnings miss, shares of BioMarin are up 1% in after-hours trading, suggesting a possible positive market reaction or investor sentiment [1]